Argos Therapeutics, Inc. (NasdaqGM:ARGS) has filed a shelf registration in the amount of $200 million. Argos Therapeutics stated, "We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include the research and development of our product pipeline, including clinical trial costs, general and administrative expenses; potential acquisition of, or investment in, companies, technologies, products or assets that complement our business; repayment and refinancing of debt; working capital and capital expenditures."